{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:30:43Z","timestamp":1790739043328,"version":"4.1.0"},"reference-count":18,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,3,12]],"date-time":"2013-03-12T00:00:00Z","timestamp":1363046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Cytopathology"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>The aim of the current study was to report the results of 7422 uCyt+\/ImmunoCyt and cytology analyses that were performed over the course of 9 years at the study institution for the evaluation and follow\u2010up of patients with urothelial carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Between January 2002 and March 2011, 2217 patients with a mean age of 69.5 years (range, 15 years\u201099 years) were enrolled in the current study. All patients seen for the follow\u2010up of bladder and\/or upper tract urothelial cancer as well as those with a history that was suspicious for bladder cancer were recruited. In all patients, a voided urinary cytology and uCyt+\/ImmunoCyt test was performed. Patients underwent routine cystoscopy as well as cystoscopy when cytology and\/or the uCyt+\/ImmunoCyt test yielded positive results. Lesions that were detected cystoscopically were biopsied and removed transurethrally. A total of 7422 uCyt+\/ImmunoCyt and cytology analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of the 7422 uCyt+\/ImmunoCyt tests and cytologies that were performed, 7075 (95.3%) were considered adequate. A total of 578 patients (with 1156 analyses) underwent biopsy and 728 (63%) samples had a histologically proven urothelial carcinoma. Overall sensitivity was 34.5% for cytology, 68.1% for uCyt+\/ImmunoCyt, and 72.8% for the 2 tests combined. Overall specificity was 97.9% for cytology, 72.3% for uCyt+\/ImmunoCyt, and 71.9% for the 2 tests combined. Cytology and the uCyt+\/ImmunoCyt test together had an overall sensitivity of 72.8%, with 59% for grade 1, 77% for grade 2, and 90% for grade 3 tumors (according to the 1973 World Health Organization grading classification system).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>On the basis of their 9\u2010year experience, the authors confirm the value of uCyt+\/ImmunoCyt and cytology analyses in the follow\u2010up of patients with non\u2013muscle\u2010invasive urothelial cancer. This could potentially reduce the number and cost of routine cystoscopic examinations in patients who are followed for bladder carcinoma. Cancer (Cancer Cytopathol) 2013;121:392\u2013397. \u00a9 2013 American Cancer Society.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncy.21287","type":"journal-article","created":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T02:50:02Z","timestamp":1363229402000},"page":"392-397","source":"Crossref","is-referenced-by-count":47,"title":["uCyt+\/ImmunoCyt and cytology in the detection of urothelial carcinoma"],"prefix":"10.1002","volume":"121","author":[{"given":"Evi","family":"Comploj","sequence":"first","affiliation":[{"name":"Department of Urology Central Hospital of Bolzano Bolzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Pathology Central Hospital of Bolzano Bolzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ambrosini\u2010Spaltro","sequence":"additional","affiliation":[{"name":"Department of Pathology Central Hospital of Bolzano Bolzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dechet","sequence":"additional","affiliation":[{"name":"Department of Urology Central Hospital of Bolzano Bolzano Italy"},{"name":"Division of Urology, Huntsman Cancer Hospital University of Utah Salt Lake City Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Palermo","sequence":"additional","affiliation":[{"name":"Department of Urology Central Hospital of Bolzano Bolzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Trenti","sequence":"additional","affiliation":[{"name":"Department of Urology Central Hospital of Bolzano Bolzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Lodde","sequence":"additional","affiliation":[{"name":"Department of Urology Central Hospital of Bolzano Bolzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Horninger","sequence":"additional","affiliation":[{"name":"Department of Urology and Pediatric Urology Medical University Innsbruck Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Pycha","sequence":"additional","affiliation":[{"name":"Department of Urology Central Hospital of Bolzano Bolzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,12]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"1","volume-title":"European Association of Urology Guidelines on Non\u2010Muscle\u2010Invasive Bladder Cancer (Ta, T1, and CIS)","author":"Babjuk M","year":"2012"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-009-0383-3"},{"key":"e_1_2_7_4_1","unstructured":"Landesgesundheitsbericht. Assessorat Bozen Provinz S\u00fcdtirol Italy: Department of Health Care\u2010Epidemiological Control Region of Alto Adige;1998:82\u201084."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.10.056"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67280-1"},{"key":"e_1_2_7_7_1","unstructured":"American Urological Association.http:\/\/www.auanet.org\/content\/guidelines-and-quality-care\/clinical-guidelines\/main-reports\/bladcan07\/chapter1.pdf. (Accessed February 2013)."},{"key":"e_1_2_7_8_1","first-page":"190","article-title":"Diagnostic utility of the ImmunoCyt\/uCyt+ test in bladder cancer","volume":"8","author":"Greene KL","year":"2006","journal-title":"Rev Urol"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000076621.71247.6c"},{"key":"e_1_2_7_10_1","first-page":"64","article-title":"Urinary markers for detecting bladder cancer","volume":"1","author":"Tinzl M","year":"2003","journal-title":"Eur Urol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21712"},{"key":"e_1_2_7_12_1","first-page":"400","article-title":"Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark","volume":"4","author":"Fradet Y","year":"1997","journal-title":"Can J Urol"},{"key":"e_1_2_7_13_1","first-page":"810","article-title":"Diagnostic value of cytology of voided urine","volume":"29","author":"Koss LG","year":"1985","journal-title":"Acta Cytol"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0b013e32830b8910"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65386-4"},{"key":"e_1_2_7_16_1","first-page":"163","article-title":"Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer","volume":"37","author":"Wiener HG","year":"1993","journal-title":"Acta Cytol"},{"key":"e_1_2_7_17_1","first-page":"1195","article-title":"Tumor\u2010associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder","volume":"1","author":"Allard P","year":"1995","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_18_1","first-page":"3641","article-title":"The value of the ImmunoCyt\/uCyt+ test in the detection and follow\u2010up of carcinoma in situ of the urinary bladder","volume":"25","author":"Mian C","year":"2005","journal-title":"Anticancer Res"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.12.023"}],"container-title":["Cancer Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncy.21287","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncy.21287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:04:04Z","timestamp":1760288644000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncy.21287"}},"subtitle":["An update on 7422 analyses"],"short-title":[],"issued":{"date-parts":[[2013,3,12]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1002\/cncy.21287"],"URL":"https:\/\/doi.org\/10.1002\/cncy.21287","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718020274.793478750","asserted-by":"object"}]},"ISSN":["1934-662X","1934-6638"],"issn-type":[{"value":"1934-662X","type":"print"},{"value":"1934-6638","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,12]]}}}